Leading the way in Cell-Free DNA

At Touchlight, we're shaping the next era of genetic medicine and we believe that the future begins with the foundation of high-quality, scalable DNA. That’s why we’ve pioneered an enzymatic manufacturing technology, dbDNA™ — a next-generation alternative to plasmid DNA that overcomes the bottlenecks of traditional systems. Our proprietary cell-free DNA manufacturing platform enables multi-gram DNA production in weeks, rather than the months taken to make plasmid DNA using traditional E.coli fermentation methods.

Whether you're developing gene therapies, mRNA vaccines, or cell-based treatments, dbDNA™ provides the speed, purity, and flexibility you need to advance your program from discovery to commercialisation.

Traditional plasmid DNA production relies on fermentation in E. coli — a process that’s slow, complex, and constrained by regulatory and manufacturing challenges. In contrast, cell-free DNA manufacturing offers:

Faster production timelines
Freedom from bacterial impurities and antibiotic resistance genes
Simplified scale-up and regulatory pathways
Compatibility with emerging modalities like mRNA, AAV, and CAR-T

dbDNA™ takes cell-free to the next level — delivering a linear, covalently closed DNA construct with no bacterial backbone and limitless payload capacity.

ARTICLE: Transforming the Economics of AAV Production Using dbDNA™

In this article, we discuss how Touchlight’s enzymatically synthesized dbDNA™ offers a safer, faster, and more efficient alternative to traditional plasmid-based AAV vector production by eliminating bacterial sequences, reducing transfection reagent use, and accelerating timelines. With broad applicability and scalability, dbDNA™ supports both research and GMP-grade needs, enabling cost-effective development and faster progression of gene therapies from preclinical to commercial stages.

ARTICLE: Enabling Cost-Effective, Rapid Access to RNA Vaccines and Therapeutics with z- dbDNA

This article explores Touchlight's innovative z-dbDNA technology and its transformative potential in RNA therapeutics, demonstrating how their enzymatic DNA production method offers significant advantages over traditional plasmid DNA fermentation, including improved yields, reduced template requirements, and enhanced scalability for mRNA, self-amplifying RNA, and other RNA-based vaccines and therapies.

ARTICLE: MegaBulb DNA: A Non-Viral ssDNA Breakthrough Revolutionising Gene Editing

Learn about Touchlight’s MegaBulb DNA™ (mbDNA)-- a groundbreaking single-stranded, circular DNA template designed to enhance CRISPR gene editing by improving efficiency, stability, and safety over traditional viral and plasmid-based methods, offering a scalable, non-viral alternative for next-generation gene therapies.

ARTICLE: Revolutionising Genetic Medicine

Download this article to learn more about how Touchlight’s enzymatically amplified dbDNA™ is revolutionizing genetic medicine by overcoming traditional plasmid DNA limitations, offering superior speed, purity, and scalability for various applications, and leading innovations in DNA manufacturing.

ARTICLE: Rewriting the Rules of Gene Therapy

Download this article to learn about how advances in lipid nanoparticles and electroporation are enhancing nonviral gene delivery methods, with Touchlight's dbDNA™ offering a scalable, high-purity alternative to plasmid DNA that eliminates bacterial sequences and improves safety for the next generation of genetic medicines.

BLOG: Enzymatic DNA vs Plasmid DNA

Read this blog about how enzymatic (cell-free) DNA offers advantages over traditional plasmid DNA through faster production, improved quality, and reduced costs.

Fast-track Your Project with Cell-Free DNA

We're leading the way in cell-free DNA

dbDNA™ is rewriting the rules

Resources

ARTICLE: Transforming the Economics of AAV Production Using dbDNA™

ARTICLE: Enabling Cost-Effective, Rapid Access to RNA Vaccines and Therapeutics with z- dbDNA

ARTICLE: MegaBulb DNA: A Non-Viral ssDNA Breakthrough Revolutionising Gene Editing

ARTICLE: Revolutionising Genetic Medicine

ARTICLE: Rewriting the Rules of Gene Therapy

BLOG: Enzymatic DNA vs Plasmid DNA

Tour Touchlight's DNA Manufacturing Facility

Ready to Accelerate Your Project? – Schedule a discovery call.